Parkside Financial Bank & Trust Has $215,000 Stock Position in Biogen Inc. (NASDAQ:BIIB)

Parkside Financial Bank & Trust lowered its position in Biogen Inc. (NASDAQ:BIIB) by 6.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,408 shares of the biotechnology company’s stock after selling 104 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Biogen were worth $215,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ashton Thomas Securities LLC acquired a new stake in shares of Biogen during the 3rd quarter valued at about $33,000. Golden State Wealth Management LLC acquired a new stake in shares of Biogen during the 4th quarter valued at about $41,000. Venturi Wealth Management LLC lifted its holdings in shares of Biogen by 73.8% during the 3rd quarter. Venturi Wealth Management LLC now owns 219 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 93 shares during the last quarter. Itau Unibanco Holding S.A. lifted its holdings in shares of Biogen by 63.8% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 231 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 90 shares during the last quarter. Finally, Quent Capital LLC lifted its holdings in shares of Biogen by 31.9% during the 4th quarter. Quent Capital LLC now owns 298 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 72 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Citigroup reduced their price target on Biogen from $160.00 to $145.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Bank of America reiterated a “neutral” rating and set a $178.00 price target on shares of Biogen in a report on Tuesday, December 10th. Bank Of America (Bofa) reduced their price target on Biogen from $178.00 to $163.00 and set a “neutral” rating for the company in a report on Tuesday, February 11th. Canaccord Genuity Group cut their price objective on Biogen from $298.00 to $265.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Finally, William Blair reissued an “outperform” rating on shares of Biogen in a research note on Monday, January 13th. Seventeen analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, Biogen presently has a consensus rating of “Hold” and an average target price of $213.33.

Biogen Stock Performance

BIIB opened at $140.50 on Friday. The stock has a market cap of $20.57 billion, a PE ratio of 12.56, a P/E/G ratio of 1.51 and a beta of -0.08. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27. Biogen Inc. has a 1 year low of $128.51 and a 1 year high of $238.00. The stock’s 50 day simple moving average is $144.43 and its 200-day simple moving average is $168.48.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. Sell-side analysts forecast that Biogen Inc. will post 15.83 EPS for the current year.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.